Chatterjee K, Gallo E

Idioma: Ingles.
Referencias bibliográficas: 10
Paginas: 148-151
Archivo PDF: 65.91 Kb.

RESUMEN

Los inhibidores de la glicoproteína IIb/IIIa son poderosos agentes antiagregantes plaquetarios y han demostrado gran utilidad en el manejo farmacológico de pacientes con síndrome coronario agudo. Existen varios compuestos de este grupo, en uso actualmente: un anticuerpo monoclonal (abciximab), dos antagonistas no peptídicos del receptor GP IIa/IIIb (tirofiban y lamifiban) y un antagonista peptídico (epitifibatide). Estos compuestos presentan entre sí importantes diferencias farmacocinéticas. Por lo tanto los riesgos y beneficios de su uso deben considerarse en función del perfil clínico de cada paciente.

REFERENCIAS (EN ESTE ARTÍCULO)

1. White HD: Non-ST-Elevation Acute Coronary Syndromes: Unstable Angina and Non-ST Elevation Myocardial Infarction. In Textbook of Cardiovascular Medicine. Ed. Eric J. Topol 2nd Edition, Lippincott, Williams & Wilkins, Philadelphia, 2002; 17: 351-384.

2. Shuman M: Hemorrhagic Disorders: Abnormalities of Platelet and Vascular Function: In: Cecil Textbook of Medicine, Eds. Goldman, Bennet. W.B. Saunders Company, Philadelphia, 2002; 184: 996-1004.

3. Bathelor WB, Tolleson TR, Huang Y, et al: Randomized Comparison of Platelet Inhibition with Abciximab, Tirofiban and Eptifibatide during Percutaneous Coronary Intervention in Acute Coronary Syndromes. The Compare Trial: Comparison of Measurements of Platelet Aggregation with Aggrastat, Reopro and Eptifibatide. Circulation 2002; 106: 1470-1476.

4. Bhatt DL, Topol EJ: Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes. JAMA 2002; 284: 1549-1558.

5. Jannuzi JL, Cannon CP, Theroux P, Boden WE: Optimizing Glycoprotein IIb/IIIa Receptor Antagonist use for the Non-ST-Segment Elevation Acute Coronary Syndromes: Risk Stratification and Therapeutic Intervention. Am Heart J 2003; 146: 764-774.

6. Boersma E, Harrington RA, Mouterno DJ, et al: Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: A Meta Analysis of all Major Randomized Clinical Trials. Lancet 2002; 359: 189-198.

7. Simoons ML: Effect of Glycoprotein IIb/IIIa Receptor Blocker Abciximab on Outcome in Patients with Acute Coronary Revascularization: The GUSTO IV – ACS Randomization Trial. Lancet 2001; 357: 1915-1924.

8. Fox KA, Poole-Wilson PA, Henderson RA, et al: Interventional Versus Conservative Treatment for Patients with Unstable Angina or Non-ST-Elevation Myocardial Infarction: The British Heart Foundation Rita 3 Randomized Trial. Randomized Intervention Trial of Unstable Angina. Lancet 2002; 360: 743-751.

9. Roffi M, Chen D, Mukherjee D, et al: Platelet Glycoprotein IIb/IIIa Inhibition in Acute Coronary Syndromes: Gradient of Benefit Related to the Revascularization Strategy. Eur Heart J 2002; 23: 1441.

10. Topol EJ, Moliterno DJ, Hermann HC, et al: Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab for the Prevention of Ischemic Events with Percutaneous Coronary Revascularization. N Eng J Med 2001; 344: 1888-1894.